| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8507632 | Acta Pharmaceutica Sinica B | 2018 | 23 Pages |
Abstract
HER3 belongs to the human epidermal growth factor receptor (HER) family. HER3 lacks or has little intrinsic tyrosine kinase activity, but it frequently co-expresses and forms heterodimers with other receptor tyrosine kinases (RTKs) to activate oncogenic signaling in cancer cells. Therapeutic inactivation of HER3 and/or its downstream signaling is required to overcome treatment resistance and improve the outcomes of cancer patients.201
Keywords
ADCCHRGTKIEGFRIGF-1RRTKncRNAPI-3KHER3long ncRNAlncRNAFDAMAPKMAPK kinasenoncoding RNAantibody-dependent cell-mediated cytotoxicityDimerizationHERheregulinoverall survivalEMTTargeted therapyFood and Drug AdministrationNSCLCNon-small cell lung cancerCell signalingphosphoinositide 3-kinaseTumor metastasisMEKTherapeutic resistanceTyrosine kinase inhibitorMicroRNAMiRNAAntibodymitogen-activated protein kinaseEpithelial-mesenchymal transitionReceptor Tyrosine Kinasehuman epidermal growth factor receptorEpidermal growth factor receptorinsulin-like growth factor-I receptor
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
Hui Lyu, Amy Han, Erik Polsdofer, Shuang Liu, Bolin Liu,